Guardant Health Jul 6, 2022 Guardant Health Licenses Genomic Cancer Assays to Adicon for Testing in China May 27, 2022 Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit Apr 13, 2022 Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests Premium Mar 17, 2022 Illumina Sues Guardant Health Over Patents, Trade Secrets, Breach of Contract Mar 14, 2022 Guardant Health Gets Japanese Approval for Tumor Mutation Profiling Liquid Biopsy Test Jan 19, 2022 Guardant Health Begins SHIELD Trial for Lung Cancer Early Detection Jan 11, 2022 JP Morgan Healthcare Conference Day 1: Novartis, Gilead, Johnson & Johnson, EQRx, Mirati, and More Nov 24, 2021 HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders Premium Nov 5, 2021 In Brief This Week: Daiichi Sankyo, AstraZeneca, Mary Bird Perkins Cancer Center, Guardant Health Nov 1, 2021 Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors Oct 5, 2021 Guardant Health Begins Study of Reveal Liquid Biopsy Test to Predict Cancer Recurrence Sep 19, 2021 ESMO Data in HER2-Positive Lung, Breast Cancer Bolster Daiichi Sankyo, AstraZeneca's Enhertu Premium Sep 2, 2021 MD Anderson Study Further Supports Using Liquid Biopsy First to Gauge EGFR Mutations in Lung Cancer Premium Jul 19, 2021 Korean AI Pathology Startup Lunit Nabs $26M Investment from Guardant Health; Plans Collaboration Jun 22, 2021 Guardant Health Targets Emerging Treatment Response Market With New ctDNA Product Premium May 28, 2021 FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen May 28, 2021 Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests May 21, 2021 FDA Approves Janssen's Rybrevant, Guardant360 CDx for EGFR Exon 20-Mutated NSCLC May 7, 2021 Guardant MRD Test Performs Well in Small Study as Tissue-Informed Debate Takes Shape Premium Apr 2, 2021 In Brief This Week: Merck, Taiho Oncology, Guardant Health, City of Hope, Bluestar Genomics Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
